Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Oncology Nursing | 4 | 2021 | 16 | 1.920 |
Why?
|
| Neoplasms | 5 | 2020 | 1359 | 1.230 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2019 | 35 | 1.210 |
Why?
|
| Antineoplastic Agents | 3 | 2018 | 663 | 0.970 |
Why?
|
| Competency-Based Education | 1 | 2024 | 30 | 0.890 |
Why?
|
| Education, Nursing, Graduate | 1 | 2024 | 51 | 0.840 |
Why?
|
| Advance Care Planning | 1 | 2021 | 62 | 0.670 |
Why?
|
| Curriculum | 1 | 2024 | 591 | 0.670 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2019 | 8 | 0.640 |
Why?
|
| Aromatase Inhibitors | 1 | 2019 | 24 | 0.630 |
Why?
|
| Lutetium | 1 | 2018 | 2 | 0.600 |
Why?
|
| Octreotide | 1 | 2018 | 4 | 0.600 |
Why?
|
| Somatostatin | 1 | 2018 | 21 | 0.600 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 201 | 0.600 |
Why?
|
| Intestinal Neoplasms | 1 | 2018 | 14 | 0.600 |
Why?
|
| Neuroendocrine Tumors | 1 | 2018 | 22 | 0.590 |
Why?
|
| Chemoprevention | 1 | 2018 | 41 | 0.580 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 78 | 0.570 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 185 | 0.560 |
Why?
|
| Carcinogenesis | 1 | 2018 | 130 | 0.530 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 90 | 0.510 |
Why?
|
| Genetic Testing | 1 | 2017 | 134 | 0.500 |
Why?
|
| DNA Damage | 1 | 2018 | 280 | 0.500 |
Why?
|
| Sepsis | 1 | 2020 | 286 | 0.500 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2015 | 19 | 0.480 |
Why?
|
| Pancreatic Neoplasms | 1 | 2018 | 341 | 0.470 |
Why?
|
| Nurse's Role | 1 | 2015 | 120 | 0.440 |
Why?
|
| Medication Adherence | 1 | 2015 | 202 | 0.420 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 166 | 0.420 |
Why?
|
| Health Promotion | 1 | 2017 | 494 | 0.390 |
Why?
|
| Drug Eruptions | 1 | 2011 | 15 | 0.370 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 474 | 0.370 |
Why?
|
| Inflammation | 1 | 2018 | 1146 | 0.360 |
Why?
|
| ErbB Receptors | 1 | 2011 | 114 | 0.350 |
Why?
|
| Genomics | 1 | 2014 | 370 | 0.350 |
Why?
|
| Breast Neoplasms | 1 | 2019 | 1199 | 0.330 |
Why?
|
| Signal Transduction | 2 | 2018 | 3033 | 0.330 |
Why?
|
| Humans | 12 | 2025 | 63283 | 0.240 |
Why?
|
| Transients and Migrants | 1 | 2025 | 26 | 0.230 |
Why?
|
| Education, Nursing, Baccalaureate | 1 | 2024 | 43 | 0.210 |
Why?
|
| Students, Nursing | 1 | 2024 | 82 | 0.200 |
Why?
|
| Goals | 1 | 2021 | 91 | 0.170 |
Why?
|
| Symptom Assessment | 1 | 2020 | 47 | 0.160 |
Why?
|
| Health Services for the Aged | 1 | 2020 | 49 | 0.160 |
Why?
|
| Clinical Competence | 1 | 2024 | 725 | 0.160 |
Why?
|
| Palliative Care | 1 | 2021 | 228 | 0.150 |
Why?
|
| Nurse Practitioners | 1 | 2020 | 117 | 0.150 |
Why?
|
| Community Health Services | 1 | 2020 | 128 | 0.150 |
Why?
|
| Female | 6 | 2025 | 32776 | 0.140 |
Why?
|
| Aged | 4 | 2020 | 14384 | 0.140 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 5443 | 0.140 |
Why?
|
| HIV Infections | 1 | 2025 | 967 | 0.140 |
Why?
|
| Adult | 4 | 2025 | 16771 | 0.140 |
Why?
|
| Middle Aged | 4 | 2025 | 17535 | 0.140 |
Why?
|
| Caregivers | 1 | 2020 | 271 | 0.130 |
Why?
|
| Communication | 1 | 2021 | 573 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 736 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2020 | 874 | 0.120 |
Why?
|
| Male | 5 | 2025 | 29799 | 0.120 |
Why?
|
| Nurse-Patient Relations | 1 | 2015 | 43 | 0.120 |
Why?
|
| Massachusetts | 2 | 2020 | 2075 | 0.120 |
Why?
|
| Boston | 1 | 2015 | 252 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2015 | 369 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 718 | 0.100 |
Why?
|
| Registries | 1 | 2017 | 884 | 0.100 |
Why?
|
| Feasibility Studies | 1 | 2015 | 568 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2017 | 357 | 0.100 |
Why?
|
| Risk Assessment | 1 | 2020 | 2071 | 0.100 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2011 | 25 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2015 | 1006 | 0.090 |
Why?
|
| Nursing Assessment | 1 | 2011 | 40 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2017 | 1988 | 0.090 |
Why?
|
| Nursing Methodology Research | 1 | 2011 | 53 | 0.090 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1254 | 0.090 |
Why?
|
| Mutation | 1 | 2017 | 2607 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2011 | 734 | 0.070 |
Why?
|
| Retrospective Studies | 1 | 2020 | 6627 | 0.070 |
Why?
|
| Child | 1 | 2017 | 4522 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 2675 | 0.070 |
Why?
|
| Young Adult | 1 | 2017 | 4683 | 0.070 |
Why?
|
| Adolescent | 1 | 2017 | 6238 | 0.060 |
Why?
|
| Haiti | 1 | 2025 | 15 | 0.060 |
Why?
|
| Dominican Republic | 1 | 2025 | 25 | 0.060 |
Why?
|
| Social Stigma | 1 | 2025 | 73 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2025 | 509 | 0.050 |
Why?
|
| Health Behavior | 1 | 2025 | 466 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2025 | 683 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 755 | 0.040 |
Why?
|